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Autoimmunity to glomerular basement membrane (GBM)
could induce Goodpasture disease, and natural
autoantibodies against GBM in the sera of normal individuals
were not reported. The aim of the study was to identify
and characterize natural autoantibodies against GBM in
normal human sera. Natural anti-GBM autoantibodies were
purified from the sera of five healthy persons by affinity
chromatography, using purified bovine a(IV)non-collagenous
(NC1) as solid-phase ligands. Antigen specificity,
immunoglobulin G (IgG) subclasses, and antibody avidity
of the natural autoantibodies were investigated by
enzyme-linked immunosorbant assay (ELISA), Western-blot
analysis, indirect immunofluorescence, and
antigen-inhibition ELISA, and compared with those of 32
patients with anti-GBM disease. Natural anti-GBM
autoantibodies could be purified from IgG fractions of all the
five persons, with an average amount of 0.5% of total IgG
fractions. Antigen specificity of the natural autoantibodies
was identified by blotting to human a(IV)NC1, reactivity to
recombinant a3(IV)NC1, and linear staining along the GBM of
normal kidney sections. Titers of the natural autoantibodies
were much lower than those of patients (1:60.6 vs 1:993.6,
Po0.001). IgG subclasses distribution of the natural
autoantibodies was restricted to IgG2 (100%) and IgG4
(100%), while for patients it was mainly IgG1 (93.8%) and
IgG4 (90.6%). Avidity of the natural autoantibodies was lower
than that of patients, the amount of a(IV)NC1 used for 50%
inhibition was 1.65 and 0.46 lg, respectively (Po0.05). In
conclusion, natural anti-GBM autoantibodies exist in normal
human sera. Antibody levels, IgG subclasses, and avidity of
the natural autoantibodies were different from those of
patients. Fine specificity of the natural autoantibodies
needed to be elucidated.
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Anti-glomerular basement membrane (GBM) disease is
widely regarded as a good example of autoantibody-mediated
disease. The disease spectrum includes patients with
glomerulonephritis and pulmonary hemorrhage (Goodpas-
ture syndrome), rapidly progressive glomerulonephritis
without clinical evidence of lung hemorrhage, and isolated
pulmonary hemorrhage.1,2 The most characteristic feature
of the disease is the presence of anti-GBM autoanti-
bodies, which deposit in a linear manner along GBM.1 The
autoantigen has been characterized mainly as the non-
collagenous (NC1) domain of a3 chain of type IV collagen
(a3(IV)NC1).3–5 Also, there are antibodies that recognize
other a chains, such as a1 and a4. It has been suggested that
the epitopes are sequestered under normal circumstances and
exposed following some physicochemical disruption, which
then allows priming of immune response.6,7
Both humoral and cellular immune responses were
implicated in disease pathogenesis.3,8 T-cell involvement
could be implied from the requirement for class-switched
autoantibody isotypes9 and strong human lymphocyte
antigen associations.10 Studies had shown that a3(IV)NC1
was expressed in the thymus,11 but some autoreactive T cells
presumably escaped the central tolerance mechanism.12
Although T-cell immunity was crucial for pathogenesis of
anti-GBM disease, the characteristics and mechanism of the
production of anti-GBM autoantibodies still remained
elusive. The pathogenicity of anti-GBM autoantibodies was
firstly demonstrated by Lerner et al.,13 who transferred
antibodies eluted from kidneys of patients with Good-
pasture’s disease to squirrel monkeys, which subsequently
developed proliferative glomerulonephritis. Further support
came from clinical studies. For example, there were
correlations between disease severity and antibody titers,14
and disease recurred if transplantation was performed in the
presence of circulating anti-GBM antibodies.15
Recent studies had shown that B cells could be subjected
to positive selection and maintained their autoreactivity.16 In
the last two decades appeared substantial evidences about
the presence of natural autoantibodies interacting with
self-antigens that were highly conserved in evolution in
healthy persons.17–19 One of the proposed roles for these
natural autoantibodies was the regulation of immune system
and control of autoimmune disease.20 Anti-GBM antibodies
had not been reported in the sera of normal individuals.3 We
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purified natural anti-GBM autoantibodies from normal
human sera by protein G affinity chromatography and then
affinity column coupling with a(IV)NC1. Characteristics of
the natural autoantibodies were further investigated and
compared with those of patients. Our results suggested that
antibody levels, immunoglobulin G (IgG) subclasses, and
antibody avidity were different between natural and disease-
associated anti-GBM autoantibodies. These might be helpful
in understanding the pathogenesis of anti-GBM disease.
RESULTS
Demographic feature of patients
Of the 32 patients with anti-GBM disease, 20 were males and
12 were females, with a mean age at 35.6716.9 years (16–74
years). In all, 18 patients presented as Goodpasture syndrome
and 14 patients presented as anti-GBM glomerulonephritis.
Anti-GBM antibodies were detectable in all the 32 patients.
Antineutrophil cytoplasmic antibodies were detectable in five
patients with four patients specified to myeloperoxidase and
one patient specified to proteinase 3.
Purification of natural anti-GBM autoantibodies from normal
human sera
IgG fractions of the five normal human sera were purified by
protein G affinity chromatography. IgG fractions of each sera
were applied to the affinity column coupled with purified
bovine a(IV)NC1. Natural anti-GBM autoantibodies could
be purified from each of the five persons. The purified
natural anti-GBM autoantibodies were then applied to the
column-containing matrix only to exclude nonspecific
binding. Natural anti-GBM autoantiboides accounted for
0.5070.17% of total IgG fractions, ranging from 0.33 to
0.69% (Table 1).
Antigen specificity of natural anti-GBM autoantibodies
Antigen specificity of the natural anti-GBM autoantibodies
was identified by enzyme-linked immunosorbant assay
(ELISA) using purified human a(IV)NC1 and recombinant
human a3(IV)NC1 as solid-phase ligands. Natural autoanti-
bodies from all the five persons exhibited reactivity with both
the antigens as same as that of the positive control. However,
the original normal sera and total IgG fractions had no
reactivity with either antigen (Figure 1).
The specificity of natural anti-GBM autoantibodies was
further confirmed by Western-blot analysis using purified
human a(IV)NC1 as solid-phase antigen. Under nonreducing
condition, the 25- and 50-kDa proteins of human a(IV)NC1
could be blotted by all the five natural autoantibodies
identical to the positive control, but not by the original
normal sera and IgG fractions (Figure 2).
The presence of autoreactive anti-GBM antibodies in the
purified natural autoantibodies and the positive control sera
was further demonstrated by indirect immunofluorescence
on sections from normal human kidney, which showed linear
IgG staining to GBM. The original normal sera and total IgG
fractions did not exhibit reactivity to GBM likewise.
Table 1 | Amount of natural anti-GBM autoantibodies purified
from the five normal sera
No.
Amount of natural
autoantibodies (mg)
Amount of IgG
fractions (mg)
Percentage in IgG
fractions (%)
1 1.25 250 0.5
2 0.82 250 0.328
3 0.83 250 0.332
4 1.94 280 0.693
5 1.47 230 0.639
Mean
value
0.5070.17
GBM=glomerular basement membrane; IgG=immunoglobulin G.
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Figure 1 | Net OD values of serum, total IgG fractions, and
purified natural anti-GBM autoantibodies of the five normal
individuals, detected by ELISA using recombinant human
a3(IV)NC1 as solid-phase antigen. Sera were diluted 1:50; IgG
fractions were diluted 1:50 equivalent to original sera; purified natural
anti-GBM autoantibodies were diluted 1:10 (Nos. 2 and 5) and 1:20
(Nos. 1, 3, and 4) equivalent to original sera.
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Figure 2 | Western-blot analysis using purified human a(IV)NC1 as
solid-phase antigen. Lane 1: standard molecular weight markers;
lane 2: TBST as blank control; lane 3: a serum from a known patient
with anti-GBM disease as positive control; lane 4: a serum from a
healthy blood donor as negative control; lanes 5, 8, 11, 14, and
17: sera from blood donors 1–5; lanes 6, 9, 12, 15, and 18: IgG
fraction from normal blood donors 1–5; lanes 7, 10, 13, 16, and 19:
affinity-purified natural autoantibodies against GBM from normal
blood donors 1–5. All sera were diluted 1:50; IgG and natural
autoantibodies were diluted 1:50 and 1:10 equivalent to original sera.
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Titers of natural anti-GBM autoantibodies compared with
those of patients
The mean titer of natural anti-GBM autoantibodies was
1:60.6 (log2 n¼ 5.9270.55), with three persons 1:80 and two
persons 1:40, while the mean titer of anti-GBM antibodies of
patients was 1:993.6 (log2 n¼ 9.9671.55), ranging from
1:100 to 1:12 800. Titers of natural autoantibodies were
much lower than those of anti-GBM antibodies from patients
(Po0.001) (Figure 3).
IgG subclasses of natural anti-GBM autoantibodies compared
with those of patients
IgG subclasses of natural anti-GBM autoantibodies from all
the five persons were restricted to IgG2 (5/5, 100%) and IgG4
(5/5, 100%). None of them was IgG1 or IgG3. For patients
with anti-GBM disease, the IgG subclasses of anti-GBM
antibodies were mainly IgG1 (30/32, 93.8%) and IgG4 (29/
32, 90.6%), with some of them restricted to IgG2 (21/32,
65.6%) and IgG3 (4/32, 12.5%) (Po0.01). IgG subclasses of
natural and disease-associated anti-GBM antibodies are
shown in Figure 4.
Avidity of natural anti-GBM autoantibodies compared with
that of patients
In antigen-inhibition ELISA, the mean amount of a(IV)NC1
used for 50% inhibition of natural anti-GBM autoantibodies
was 1.65 mg (log2 n¼ 0.7270.55), with three persons 1.25 mg
and two persons 2.5 mg. For anti-GBM antibodies of
patients, the amount of a(IV)NC1 needed for 50% inhi-
bition ranged from 0.02 to 5 mg, with a mean value at 0.46 mg
(log2 n¼1.1171.92). The avidity of natural anti-GBM
autoantibodies was lower than that of patients (Po0.05)
(Figure 5).
DISCUSSION
In the current study, we demonstrated the presence of natural
autoantibodies against GBM in normal human sera, which
could be purified by affinity chromatography and accounted
for about 0.5% of total IgG fractions. The antigen specificity
of the natural autoantibodies might be the same as that of
patients; however, fine specificity was still unclear. Titers and
avidity of the natural autoantibodies were lower than those of
patients, and IgG subclasses were exclusively restricted to
IgG2 and IgG4.
Natural anti-GBM autoantibodies could only be obtained
from affinity-purified IgG fractions, while nothing was
obtained when original normal sera were applied directly to
the affinity column coupled with a(IV)NC1 (data not
shown). This result and no report of anti-GBM antibodies
detected in normal sera3 indicated that the autoreactivity of
anti-GBM antibodies in whole serum was much lower than
that of anti-GBM antibodies in purified IgG fractions. It was
suggested that autologous IgM might contribute to control
the expression of natural autoreactive IgG repertoire in whole
serum, through V region-dependent interactions.21 Thus, in
normal human serum, IgG autoreactivity against GBM could
be found barely after separation of IgG fractions from other
serum proteins.
Repertoires of natural anti-GBM autoantibodies from
each of the five individuals were nearly the same in terms of
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Figure 3 | Titers of natural anti-GBM autoantibodies (m) were
compared with those of anti-GBM antibodies in sera from
patients (~). NHS: normal human sera. *Po0.001.
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Figure 4 | IgG subclasses of natural anti-GBM autoantibodies (&)
were compared with that of anti-GBM antibodies from patients
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Figure 5 | Avidity of natural anti-GBM autoantibodies (m) was
compared with that of anti-GBM antibodies in sera from patients
(~). NHS: normal human sera. *Po0.05.
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antigen specificity, antibody titers, avidity, and IgG subclass
restriction. This result indicated a settled and strictly
regulated system of natural autoantibodies in normal
population. One of the main characteristics of this network
was the maintenance of an optimal level of production and
content of natural autoantibodies, as well as elimination of
the occasional perturbations of such level.22,23
Natural anti-GBM autoantibodies could recognize
self-antigens that were also targeted during progression
of autoimmune disease. Thus, attempts had been made to
distinguish natural autoantibodies from those associated
with pathogenicity. We found that natural and disease-
associated autoantibodies against GBM differed mainly in
their antibody quantity, IgG subclasses, and antibody
avidity.
The low titers (1:15 vs 1:993.6) and low quantities (0.5%
of IgG) of natural anti-GBM autoantibodies were identified
in our study, with the latter 1% in patients found by
Hellmark et al.24 This result implied that the quantitative
difference between natural and disease-associated autoanti-
bodies might play a role in pathogenesis of disease. Recent
evidence suggested that natural autoantibodies were con-
sidered pathological only when they exceed a certain cut-off
level.16,25–28 In anti-GBM disease, we speculated that the
disturbance of the tolerogenic pathway and start of autoimm-
unity might be due to the enhancive access of autoantigen, in
the circumstances of smoking, infection, exposure to
hydrocarbons, or degradation by reactive oxygen species.1,7
At that moment higher levels of autoantibodies would be
formed, which might give rise to the pathological events of
anti-GBM disease.
We found that natural IgG autoantibodies to GBM were
predominantly of IgG2 and IgG4 isotypes, while in patients
they were mainly IgG1 and IgG4. This might be of interest in
view of previous findings that autoantibodies specific for
DNA in healthy individuals were of IgG2 subclass, while in
systemic lupus erythematosus patients they were mostly
IgG1.29 It should be mentioned that autoantibodies of IgG1
and IgG3 subclasses might have a distinct role in pathogen-
esis, as these two subclasses were known to be able to activate
the complement.30 Once activated, complement chemotactic
factors might then attract effector cells such as neutrophils
and macrophages, which had an established role in mediating
glomerulonephritis.31
The class-switching of anti-GBM autoantibodies suggested
that T-cell involvement was required for disease initiation.
Circulating T cells from patients had been identified to react
with a3(IV)NC1 autoantigen. The majority of autoreactive T
cells were found at the time of the disease and decreased
during recovery and convalescent periods.12 As suggested by
Cairns et al.,32 changes in peptide processing and presenta-
tion might generate epitopes previously not tolerated by the
immune system and initiate disease. Thus, the elevated
frequency of autoreactive T cells and the might happened
change of epitopes recognized by them were supposed to play
a role in pathogenesis of disease.
In the current study, we also found that avidity of natural
anti-GBM autoantibodies was lower than that of patients.
The moderate avidity together with low affinity was a
characteristic of natural autoantibodies.33 This property was
predictable and compatible with the regulatory roles of
natural autoantibodies. However, since the avidity of anti-
GBM antibodies in patients was various in a wide range and
was associated with disease severity,34 the lower avidity of
natural autoantibodies compared to the disease-associated
antibodies needed to be confirmed and elucidated by further
investigation.
The antigen specificity of natural anti-GBM autoanti-
bodies was identified by blotting of purified human
a(IV)NC1. Recognition to NC1 domains of a3 chain was
further confirmed using recombinant a3(IV)NC1. However,
the fine specificity of the natural autoantibodies was still
unclear. Since there were reports about autoantibodies
recognizing other a chains, we suspected as well that the
amount of 0.5% of total IgG fractions might be the gross of
natural autoantibodies recognizing different a chains or
different epitopes. Evidence had suggested that, during the
course of disease, at least a population of natural auto-
antibodies was subjected to changes of its fine specificity,
probably through antigen-driven somatic mutations.35–37
Thus, further researches about natural anti-GBM autoanti-
bodies should be stressed on fine epitope mapping of the
autoreactive B lymphocytes.
In conclusion, natural anti-GBM autoantibodies exist in
normal human sera. Antibody levels, IgG subclasses, and
avidity of the natural autoantibodies were different from
those of patients with anti-GBM disease. Further studies
were needed to elucidate the role of natural anti-GBM
autoantibodies in autoimmunity of normal individuals and
pathogenesis of anti-GBM disease.
MATERIALS AND METHODS
Sera
Normal human sera were obtained from five normal healthy blood
donors, including three males and two females, with an average age
at 23.675.5 (18–30) years.
Sera from 32 patients with biopsy-proven anti-GBM disease were
collected from 1991 to 2002 and preserved at 201C. All these
patients were diagnosed in the Renal Division and Institute of
Nephrology, Peking University First Hospital. All the sera were
obtained on diagnosis before treatment with plasma exchange or
immunosuppression. Anti-GBM antibodies were detected by ELISA
using collagenase-solubilized human GBM as solid-phase ligands.
Antineutrophil cytoplasmic antibodies were screened by indirect
immunofluorescence assay and ELISA for myeloperoxidase-anti-
neutrophil cytoplasmic antibodies and proteinase 3-antineutrophil
cytoplasmic antibodies as described.38
Preparation of a(IV)NC1
Preparation of human and bovine a(IV)NC1 was performed as
described previously.24,34,39 In brief, glomeruli were isolated by
differential sieving, and cells of glomeruli were lysed in 5 mmol/l
Tris-HCl, pH 7.4, 0.02% (w/v) sodium azide, and protease
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inhibitors, at 41C overnight. Crude GBM was suspended in 4% (w/v)
deoxycholic acid, 0.02% sodium azide, and protease inhibitors at
371C for 2.5 h. After extraction with detergent, GBM was
resuspended in deoxyribonuclase I (50 Kunitz U/ml), 0.02% sodium
azide at 371C for 1 h, and then digested by bacterial collagenase I
(Sigma, St Louis, MO, USA) at 1:10 enzyme/protein ratio, in
N-hydroxyethylpiperazine-N0-ethane sulfonic acid buffer (50 mmol/
l N-hydroxyethylpiperazine-N0-ethane sulfonic acid, pH 7.5 with
10 mmol/l CaCl2 and protease inhibitors) at 371C for 20 h. After
inactivating collagenase at 601C for 10 min, the supernatant (soluble
GBM proteins) was applied to a Resource Q ion exchange
chromatography column (Amersham Pharmacia, Freiburg, Sweden)
with 50 mmol/l Tris-HCl, pH 7.5 as starting buffer, and 50 mmol/l
Tris-HCl and 1 mol/l NaCl, pH 7.5 as eluting buffer, by a gradient of
20 column volumes. NC1 domains, which did not bind to the
column, were collected, concentrated, and dialyzed against 0.01 mol/l
phosphate-buffered saline (PBS).
Affinity chromatography
Purified bovine a(IV)NC1 (10 mg) was coupled to 10 ml cyanogen
bromide activated-Sepharose 4B gel (Amersham Pharmacia) with
0.1 mol/l NaHCO3 and 0.5 mol/l NaCl, pH 8.3 as coupling buffer at
room temperature for 2 h, and blocked with 0.2 mol/l glycine, pH
8.0 at room temperature for 2 h.
IgG fractions were purified by protein G affinity column
(Amersham Pharmacia) with 0.01 mol/l PBS, pH 7.4 as starting
buffer and 0.1 mol/l glycine, pH 2.7 as eluting buffer, at a flow rate
of 2 ml/min at room temperature. IgG was eluted and neutralized
to pH 7.0 by 2 mol/l Tris-HCl, pH 9.0 immediately, concentrated by
ultrafiltration cell YM10 (Amicon, Bedford, MA, USA) and dialyzed
against PBS.
Normal human IgG was applied to the affinity column coupled
with purified bovine a(IV)NC1 with 0.01 mol/l PBS, pH 7.4 as
starting buffer and 0.05 mol/l glycine, 0.5 mol/l NaCl, pH 2.7 as
eluting buffer, at a flow rate of 1 ml/min at room temperature.
Natural anti-GBM autoantibodies were eluted, neutralized to pH
7.0, concentrated, and dialyzed against PBS.
The natural anti-GBM autoantibodies were then applied to an
affinity column containing cyanogen bromide activated-Sepharose
4B gel only with 0.01 mol/l PBS, pH 7.4 as starting buffer and
0.05 mol/l glycine, 0.5 mol/l NaCl, pH 2.7 as eluting buffer, at a flow
rate at 1 ml/min at room temperature. Natural autoantibodies,
which did not bind to the column, were washed out, concentrated,
and dialysed against PBS.
Western-blot analysis
The purified human a(IV)NC1 were electrophoresed with 12.5%
sodium dodecylsulfate polyacrylamide gel at 20 mA under non-
reducing conditions. Then, the proteins were transferred to a
nitrocellulose paper (Schleicher&Schuell, Dassel, Germany) by an
electrophoretic semi-dry blotting system (Amersham Pharmacia) at
0.08 mA/cm2 for 70 min. The nitrocellulose paper was blocked in
Tris-buffered saline with Tween and milk (TBSTM) buffer
(0.01 mol/l Tris-HCl, pH 7.2, 0.15 mol/l NaCl, 0.1% (v/v) Tween
20, 20 g/l skimmed milk) for 30 min at room temperature and cut
into strips. The strips were incubated with sera diluted 1:50, IgG and
natural autoantibodies diluted 1:50 and 1:10 equivalent to original
sera in TBSTM at 41C overnight. After three washes with TBST,
the strips were incubated with alkaline phosphatase-conjugated
anti-human IgG (Sigma), diluted 1:6000 in TBSTM for 1 h at
room temperature. The binding was detected by adding alkaline
phosphatase substrate nitroblue tetrazolium (Sigma) and 5-bromo-
4-chloro-3-indolyl phosphate (Sigma).
Indirect immunofluorescence assay
Slides of frozen normal human kidney sections were incubated with
sera, total IgG, and natural autoantibodies diluted with 0.01 mol/l
PBS, at 371C for 30 min. A known anti-GBM antibody positive
serum was used as positive control. The slides were then incubated
with 1:40 diluted fluorescein isothiocyanate-conjugated monospe-
cific antisera to human IgG (Dako, Denmark), at 371C for 30 min.
The sections were examined with a fluorescent microscope (Nikon,
Japan). Visualization of smooth linear deposits along the walls of
glomerular capillaries with grade X2þ (graded from 7 to 4þ )
was indicative of anti-GBM antibodies.
a(IV)NC1-specific ELISA
Purified a(IV)NC1 was diluted to 1 mg/ml and recombinant human
a3(IV)NC1 (kindly provided by Professor T Hellmark, Lund
University, Sweden) was diluted to 0.5 mg/ml with 0.05 mol/l
bicarbonate buffer, pH 9.6, and were coated on wells of one-half
polystyrene microtiter plates (Costar, West Grove, PA, USA), at 371C
for 1 h. Bovine serum albumin diluted 2mg/ml was coated as well and
was used to exclude non-specific binding. The other half was coated
with bicarbonate buffer a lone to act as antigen-free wells. Test sera
were diluted 1:50, total IgG and natural autoantibodies were diluted
1:50 and 1:10 equivalent to original sera with PBS containing 0.1%
Tween 20 (PBS with bovine serum albumin (PBST)) and coated in
duplication, at 371C for 30 min. The volume for each step was 100ml
and, between incubations, plates were washed three times with PBST.
Binding was detected with horseradish peroxidase-conjugated goat
anti-human IgG (fragment c (Fc)) (Jackson) 1:5000 in PBST. The
peroxidase substrate o-phenylenediamine was used at 0.4 mg/ml in
0.03 mmol/l citrate phosphate buffer, pH 5.0. Results were recorded as
the net optical density (OD) 490 nm (average value of antigen-coated
wells minus antigen-free wells) by a microplate reader (Bio-Rad).
Each plate contained positive, negative, and blank controls. The cut-
off value was set as the meanþ 3 s.d. (net OD: 0.173) of 100 healthy
blood donors. In all, 50 sera from patients with other renal diseases
were used as disease controls.
Titers of anti-GBM antibodies
Titers of anti-GBM antibodies were detected using ELISA as
described above. Sera were diluted in a two-fold manner from
1:50 to 1:41 200 and natural autoantibodies were diluted from 1:5 to
1:320 equivalent to original sera. Titers were defined as the highest
dilution of the sample which was still positive.
IgG subclasses of anti-GBM antibodies
The IgG subclasses of anti-GBM antibodies were detected using
ELISA as described above. Binding of each IgG subclass was detected
by horseradish peroxidase-conjugated monoclonal mouse anti-
human IgG1 (4E3), IgG2 (HP6014), IgG3 (HP6050) and IgG4
(HP6025) subclass antibodies (Southern Biotech, Birmingham, AL,
USA) diluted 1:1000 in PBST. The cut-off value of each IgG subclass
was set as described above (net OD: IgG1 0.231, IgG2 0.172, IgG3
0.176, and IgG4 0.163).
Avidity of anti-GBM antibodies
Avidity of anti-GBM antibodies was examined as described,40 with
minor modifications. Sera and natural autoantibodies were diluted
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in PBST, in order to give the same absorbance units (net OD 0.9)
after 30 min in development. Samples were pre-incubated at 41C
overnight with purified bovine a(IV)NC1 diluted from 0.1 to
200mg/ml in a two-fold manner. Bound antibodies were detected as
described above. The amount of a(IV)NC1 needed for 50%
inhibition was used as the measure of avidity.
Statistical test
Values were expressed as mean7s.d. Titers of antibodies and the
amount of a(IV)NC1 used in antigen-inhibition ELISA were
expressed as the logarithm of two (log2 n). Student’s t-test (mean)
or Fisher’s exact test (frequencies) was used in statistical analyses of
the comparison between natural and disease-associated autoanti-
bodies. Po0.05 was regarded as significant. All statistical analyses
were carried out using SPSS v10.0 (SPSS Inc., Chicago, IL) statistics
package.
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